

RETRACTED ARTICLE: In situ Injection of pH- and Temperature-Sensitive Nanomaterials Increases Chemo-Photothermal Efficacy by Alleviating the Tumor Immunosuppressive Microenvironment

Jianhua Liu^{1,*}, Liantao Guo^{1,*}, Yan Rao², Weijie Zheng¹, Dongcheng Gan¹, Jing Zhang², Fan Luo¹, Xinwen Kuang¹, Saraswati Sukumar³, Yi Tu¹, Chuang Chen¹, Shengrong Sun¹

¹Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China; ²Animal Biosafety Level III Laboratory at the Center for Animal Experiment, Wuhan University School of Medicine, Wuhan, People's Republic of China; ³Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

*These authors contributed equally to this work

Correspondence: Shengrong Sun; Chuang Chen, Tel +86-13707198696; +86-1370664785, Email sunshengrong@sina.com; chenc2469@163.com

Purpose: Triple-negative breast cancer (TNBC) is challenging to treat with traditional “standard of care” therapy due to the lack of targetable biomarkers and rapid progression to distant metastasis.

Methods: We synthesized a novel combination regimen that included chemotherapy and photothermal therapy (PTT) to address this problem. Here, we tested a magnetic nanosystem (MNs-PEG/IR780-DOX micelles) loaded with the near-infrared (NIR) photothermal agent IR780 and doxorubicin (DOX) to achieve chemo-photothermal and boost antitumor immunity. Intraductal (i.duc) administration of MNs-PEG/IR780-DOX could increase the concentration of the drug in the tumor while reducing systemic side effects.

Results: We showed more uptake of MNs-PEG/IR780-DOX by 4T1-luc cells and higher penetration in the tumor. MNs-PEG/IR780-DOX exhibited excellent photothermal conversion in vivo and in vitro. The release of DOX from MNs-PEG/IR780-DOX is pH- and temperature-sensitive. Facilitated i.duc administration, MNs-PEG/IR780-DOX displayed antitumor effects and prevented distant organs metastasis under NIR laser (L) irradiation and magnetic field (MF) while avoiding DOX-induced toxicity. More importantly, MNs-PEG/IR780-DOX alleviated tumor immunosuppressive microenvironment by increasing tumor CD8⁺ T cells infiltration and reducing the proportion of myeloid-derived suppressor cells (MDSCs) and Tregs.

Conclusion: Intraductal administration of pH- and temperature-sensitive MNs-PEG/IR780-DOX with L and MF had the potential for achieving minimally invasive, targeted, and accurate treatment of TNBC.

Keywords: triple-negative breast cancer, photothermal therapy, near-infrared image, intraductal administration, tumor immunosuppressive microenvironment

Introduction

Breast cancer ranks first among the most prevalent malignancies globally.¹ Triple-negative breast cancer (TNBC) consists of 12–17% of breast cancer cases.^{2,3} Due to the absence or low expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2), hormone therapy and HER2 inhibitors are ineffective in TNBC, leading to a poor prognosis of TNBC.

Chemotherapy, particularly doxorubicin (DOX), remains the primary adjuvant treatment for patients with TNBC.⁴ However, several significant issues, such as severe cardiotoxicity and poor tumor penetration, restrict the DOX use.^{5,6} Therefore, it is necessary to improve the permeability and retention of drugs in tumors while reducing toxicity.

Nanocarrier-based drug delivery systems developed rapidly to improve anti-cancer therapy.⁷ Compared with the traditional free drugs, nano carrier-based drug delivery has unique advantages. It can increase preferential tumor accumulation due to passive targeting⁸ or active targeting by conjugation of ligands that recognize “receptor” molecules expressed on cancer cells, such as hyaluronic acid (HA),⁹ TAT,¹⁰ iRGD,¹¹ polysorbate 80,¹² and chlorotoxin.¹³ Nevertheless, the complexity of nano-delivery system design and the lack of molecules specifically expressed on cancer cells limit their therapeutic effectiveness.^{14,15} Thus, it is difficult to eradicate tumors using nano-platform chemotherapy alone. Combined with other therapies, this could break through the limitations of each treatment, resulting in collaborative enhanced super-additive therapeutic outcomes (namely “1 + 1 > 2”).^{16,17}

Nanoparticle-mediated photothermal therapy (PTT) has been applied as an adjuvant cancer treatment strategy to improve the therapeutic effect of chemotherapy.^{18,19} PTT induces protein denaturation and aggregation, physical alteration of chromatin, and inhibition of DNA synthesis and repair.²⁰ Photothermal destruction-induced tumor cell immunogenic death (ICD) results in the death of cancer cells in an immune manner, which subsequently boosts antitumor immunity.^{21,22} However, systemic administration of drugs has disadvantages such as short blood circulation time, non-specific biological distribution tissues, and fast excretion, which increase design difficulty and significantly limit drug efficacy. In light of these, local administration may be a promising therapeutic strategy.

Local administration of therapeutics is successfully undergone clinically in cancer trials.²³ It aims to achieve adequate therapeutic levels at the target site while reducing off-target effects by minimizing systemic exposure. Local therapy, a type of local therapy, has shown potential in various chemo-, radio-, and biological therapies for breast cancer.²⁴

Herein, we rationally designed a pegylated magnetic micelle (MNs-PEG/IR780-DOX), which has the following advantages: (1) enhanced permeability and retention (EPR); (2) a magnetic Fe₃O₄ core that contributes to magnetic targeting; (3) pH- and temperature-sensitive to achieve precise temporal and spatial control of release; (4) photothermal conversion capacity of IR780 and Fe₃O₄. We assessed the anti-tumor efficacy of MNs-PEG/IR780-DOX in the 4T1-luc-bearing tumor model via i.d. injection. In addition, the safety and tolerability of MNs-PEG/IR780-DOX were tested by blood biochemistry and histological analysis of major organs. We showed that the anti-tumor efficacy could be improved, and side effects can be reduced through minimally invasive, dual-targeted multi-therapy and boosting anti-tumor immunity.

Materials and Methods

Cell Lines and Reagents

4T1-luc cells were supplied by the Institute of Chinese Academy of Science, China. 4T1-luc cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin at 37°C in 5% CO₂. DOX was purchased from Hefei Bomei Biotechnology Co., LTD. (Hefei, China). DSPE-mPEG 2000 was purchased from Avitol Pharmaceutical Technology Co., LTD. (Shanghai, China). DSPE-PEG-COOH was purchased from Carbon Water Technology Co., LTD. (Guangzhou, China). IR780 was purchased from St. Louis, (MO, USA). Fe₃O₄ COA was purchased from Dona Biological Technology Co., LTD. (Nanjing, China).

Preparation of MNs-PEG/IR780-DOX

DSPE-mPEG 2000 (75 mg), DSPE-PEG-COOH (25 mg), and IR780 (5 mg) were added with 2 mL chloroform containing doxorubicin (1.41 mg/mL) ultrasonic dissolution. Add Fe (5 mg) to the solution and mix it by ultrasonic. The mixture was transferred to an eggplant flask, and 2 mL of deionized water was added. The water and chloroform were mixed by ultrasound. The eggplant-shaped bottle was connected to the explosion-proof bottle and put into the rotary evaporation device. Reverse rotary evaporation was carried out at 70°C and 20 rpm. Open the air valve immediately to prevent the solution from bursting. When the chloroform was completely removed from the eggplant flask, DSPE-PEG-Fe coated with IR780 was obtained by pure water. Finally, the concentrated DSPE-PEG-Fe was removed by magnetic separation. The concentration of Fe was determined and set to 1 mg/mL.

IR780, Fe and DOX Loading Evaluation

100 μ L of purified DOX-loaded DSPE-PEG- Fe_3O_4 nanoparticles of IR780 were added into 900 mL methanol and 90 mL Tween20 solution for demulsification and ultrasonic dissolution of the drug. The content of DOX in PLGA-PEG-COOH capsules was determined by UV-vis spectroscopy. The absorption of doxorubicin at 495 nm was calculated.

Characterization

The structure and element distribution of the MNs-PEG/IR780-DOX were analyzed by a transmission electron microscope (TEM, SHZ-D, JEOL, Japan) equipped with an energy-dispersive spectrometer. The zeta-potential and particle size distributions of the samples were determined by a Malvern Zetasizer (Nano ZS, Malvern, UK).

Calculation of Photothermal Conversion Efficiency

MNs-PEG/IR780-DOX were exposed under 808 nm laser irradiation (0.5, 1.0 and 1.5 W/cm^2) for 3 min. Deionized water was then exposed under 808 nm laser irradiation (1.5 W/cm^2) for 3 min. The thermocouple monitored the temperature of the samples for 3 min, and photographs of the temperature were recorded using a FLUKE T420 IR thermal camera. Then, the laser was turned off, and the solution temperatures were recorded every 20s for another 15 min. The following formula can define the photothermal conversion efficiency:

$$\eta = \frac{hA(T_{max} - T_0) - Q_0}{I(1 - 10^{-\tau})} \quad (1)$$

In vitro Cellular Uptake of MNs-PEG/IR780-DOX

4T1-luc cells were plated in a 6-well cell culture plate at a concentration of 5×10^5 cells per well. The cells were then treated with 4 $\mu\text{g}/\text{mL}$ free DOX, MNs-PEG/IR780-DOX (at equal DOX concentration with 4 $\mu\text{g}/\text{mL}$) for 1, 2, and 3 h. The cellular uptake of DOX was measured quantitatively by the fluorescence intensity per cell using flow cytometry. Flow cytometry analysis was performed using a CytoFLEX flow cytometer (Beckman Coulter, Fullerton, CA, USA).

Confocal Laser Scanning Microscopy (CLSM)

4T1-luc cells were seeded at a density of 8×10^4 cells in 3.5-cm dishes with coverslips for 24 h and then cultured with free DOX and MNs-PEG/IR780-DOX (at equal DOX concentration with 4 $\mu\text{g}/\text{mL}$) for 3 h at 37°C, followed by washing with PBS for three times to remove extracellular DOX fully. Then, the cells were stained with 300 nM of LysoTracker Green (Ex 504 nm, Em 511 nm Molecular Probes, USA) for 30 min and 5 mg/mL Hoechst 33,342 (Ex 345 nm, Em 478 nm, Beyotime, China) for another 10 min. The cells were rinsed with PBS three times after staining and fixed with 4% paraformaldehyde for 20 min at room temperature and subjected to CLSM. DOX (Ex 488 nm, Em 570 nm). All images were collected with the same instrumental settings and analyzed with image analysis software. The cellular fluorescence images were recorded using a Zeiss microscope (Axio Observer Z1).

In vitro Cytotoxicity Assay

The dose-dependent effects of DOX and MNs-PEG/IR780-DOX on 4T1-luc cells viability were determined with Cell Counting Kit 8 (CCK-8) assay (Dojindo) according to the manufacturer's instructions.²⁵ 4T1-luc cells were plated in a 96-well cell culture plate at a concentration of 1×10^4 cells per well and incubated with concentrations of MNs-PEG/IR780-DOX ranging from 0.007813 to 32 $\mu\text{g}/\text{mL}$. The exact amounts of free DOX were added to parallel wells as controls. The effects of PBS, MNs-PEG/IR780, Laser, MNs-PEG/IR780 + Laser, MNs-PEG/IR780-DOX + Laser (at equal DOX concentration with 4 $\mu\text{g}/\text{mL}$) on 4T1-luc cell viability also were assessed. After 24 h treatment, the effect of treatments on cell proliferation was determined using CCK-8 assay.

4T1-luc Tumor-Bearing Model and Imaging

Before all the experiments, female BALB/c mice (6–8 months old, 25–30 g) were given free access to food and water. All animal studies were reviewed and approved by the Laboratory Animal Welfare & Ethics Committee (IACUC) of Renmin Hospital of Wuhan University (Issue No. 20200702). All animal experiments complied with the Guide for Care and Use of Laboratory Animals by the Institute of Laboratory Animal Research. The tumor model was grown by i.duc administration 20 μL of 4T1-luc cells with a concentration of 1×10^5 cells in PBS into the 4th right gland of each BALB/c mouse under anesthesia. Tumors localized injected with PBS were set up as the control group. At different predetermined time points, the mice were anesthetized and scanned by an in vivo imaging system (PerkinElmer, IVIS Spectrum). The signal of IR780 was collected. Tumor volume according to bioluminescence intensity is determined by an IVIS imaging system. NIR fluorescence images were collected with excitation at 710 nm and emission at 780 nm.

Tumor Penetration of MNs-PEG/IR780-DOX

Tumor-bearing (4T1-luc) BALB/c mice were randomly divided into MNs-PEG/IR780-DOX, MNs-PEG/IR780-DOX + MF groups ($n = 3$, each group) 3 days after inoculation. Twenty-four hours after i.duc administration with 20 μL MNs-PEG/IR780-DOX of mice were photographed by in vivo imaging system (IVIS) Lumina LT Series III (Perkin Elmer). The two groups of mice were sacrificed after being observed; tumors and all major tissues, including the heart, liver, spleen, lung, kidney, and lymph nodes (LNs), were also collected and photographed. The radiance of each photograph was analyzed by using Living Image 4.5 software.

In vivo Tumor and Tissue Distribution of DOX

Tumors and all the major tissues of each group above were fixed with 4% paraformaldehyde, then equilibrated in 30% sucrose for 24 h. Sections of the tissues were cut at a thickness of 15 μm on a freezing microtome. The tumor sections were permeabilized with Triton X-100 and blocked by 10% normal calf serum. The DAPI (blue) was used to stain the nuclei and DOX (red, Ex 488nm, Em 570nm) of both tumor and major tissue sections.

In vivo Photothermal Conversion

The 4T1-luc tumor-bearing model was established as described above. Subsequently, on day 3 after tumor inoculation, we divided the mice into 3 groups ($n = 3$). PBS, MNs-PEG/IR780-DOX + L, MNs-PEG/IR780-DOX + MF + L (DOX, 1 mg/kg). MNs-PEG/IR780-DOX or PBS (20 μL) administered i.duc into the 4th right mammary gland with or without MF. The tumor area was then irradiated with an 808 nm laser at 15 W/cm^2 for 10 min. During irradiation, thermal images of the mice were obtained with a compact thermal imaging camera (FLIR E60).

DOX Release Test

In vitro DOX release from MNs-PEG/IR780-DOX was performed in ddH₂O buffer at pH values of 7.4, 6.0, and 4.5, tiring at 37°C for the DOX release. DOX release profiles from MNs-PEG/IR780-DOX with or without NIR laser irradiation at a power density of 0.15 W/cm^2 . At selected time intervals, the supernatant was collected after centrifugation and determined by a UV-vis spectrophotometer at 495 nm.

In vivo Tumor Growth Determination

Two methods determined the tumor volumes of the mice. One is to measure the intensity of the bioluminescence signal through imaging in vivo. Another is to determine tumor size by measuring the length and width of the tumors with a digital caliper every 3 days. The tumor volumes were calculated as $\text{volume (mm}^3\text{)} = \text{length} \times \text{width}^2 \times 0.5$.

Flow Cytometry

Tumors and spleens excised from mice were placed on ice. Tumor single-cell suspensions were obtained by gentleMACS™ dissociator and digestive enzyme (Miltenyi Biotec) according to the manufacturer's instructions. Spleens were squashed and filtered (70 μm). The obtained cell suspensions were removed from red blood cells using FACS lysing solution (BD Biosciences). After 1–2 washes with PBS containing 10% FBS, cells were blocked with anti-CD16/32 Fc blocking antibody

(1:25, BD Biosciences, 2.4G2) for 20 minutes. Then, cells were incubated for 30 minutes with antibodies targeting the cell-surface markers anti-CD45 (1:500, eBioscience, 30-F11), anti-CD3 (1:500, Biolegend, 17A2), anti-CD4 (1:500, Biolegend, RM4-5), anti-CD8a (1:500, Biolegend, 53-6.7), anti-CD11b (1:500, Biolegend, M1/70), anti-F4/80 (1:500, Biolegend, BM8), anti-CD86 (1:500, Biolegend, GL-1), anti-CD206 (1:2000, Biolegend, C068C2), anti-CD11c (1:500, Biolegend, N418), anti-Gr-1 (1:500, Biolegend, RB6-8C5) and anti-CD25 (1:500, Biolegend, 3C7). Flow cytometry analysis was performed using a CytoFLEX flow cytometer (Beckman Coulter, Fullerton, CA, USA).

Statistical Analysis

All data were collected in triplicate and reported as mean and standard deviation. Comparison between the groups was performed using a *t*-test. One-way ANOVA was used to analyze multiple comparisons by GraphPad Prism 8.0. #*p* > 0.05, **p* < 0.05, ***p* < 0.01, ****p* < 0.001, and *****p* < 0.0001; &*p* < 0.05, &&*p* < 0.01, and &&&&*p* < 0.001.

Results

Synthesis and Characterization of MNs-PEG/IR780-DOX

Figure 1 illustrates that the tumor growth and metastasis of orthotopic xenograft 4T1-luc-bearing mice and that the synthesis and application of MNs-PEG/IR780-DOX effectively inhibits tumor growth and distant metastasis with NIR laser and MF, and the mechanism of inducing antitumor immunity. The concentration of DOX in MNs-PEG/IR780-DOX was 1.6mg/mL, determined by UV-vis spectroscopy.

We firstly investigated the characterization of MNs-PEG/IR780-DOX micelles. As shown in Figure S1, dynamic light scattering (DLS) measurements indicated MNs-PEG/IR780-DOX particle size was around 160 nm. MNs-PEG/IR780-DOX exhibited similar negative zeta potentials within -32 mV (Figure S2). MNs-PEG/IR780-DOX were dimensionally homogeneous, as shown by TEM (Figure S3). To verify the stability of MNs-PEG/IR780-DOX in vitro, we incubated it in a 37°C water bath for 48 h. At 0, 12, 24, and 48 h, particle size, zeta potentials were detected, and photographs were taken. As shown in Figure S4A and B, there was no noticeable change in the 48 h particle size and zeta potentials. In the light microscope, the material remained unchanged from 0 h to 48 h (Figure S4C).

We investigate the photothermal effect of MNs-PEG/IR780-DOX in vitro. MNs-PEG/IR780-DOX were irradiated with an 808 nm NIR laser on and off at a power density of 0.5, 1.0, and 1.5 W/cm² for 5 min; ddH₂O was used as a control treated in 1.5 W/cm² for 5 min. Heating and cooling curves of MNs-PEG/IR780-DOX were recorded by an infrared thermal camera (Figure 2A). As shown in Figure 2B, after 0.5, 1.0, and 1.5 W/cm² 808 nm laser irradiation for 5 minutes, the temperature of MNs-PEG/IR780-DOX increased by 8.6°C, 29.3°C, and 37.3°C, respectively. In stark contrast, the temperature of ddH₂O only increased by 2.6°C after 1.5 W/cm² NIR laser irradiation for 5 minutes. We calculated the photothermal conversion efficiency $\eta = 50.01\%$.

Next, we tested the photothermal effect of MNs-PEG/IR780-DOX in the 4T1-luc-bearing tumor model. Three days after tumor inoculation, we randomly divided the mice into 3 groups (n = 3): PBS, MNs-PEG/IR780-DOX + L, MNs-PEG/IR780-DOX + MF + L. MNs-PEG/IR780-DOX (DOX, 1mg/kg) or PBS (20 μ L) was administered i.duc into the 4th right mammary gland with or without MF. The tumor area was then irradiated with an 808 nm NIR laser at 0.5 W/cm² for 10 min. The thermal image of the whole mouse was recorded by the infrared thermal camera post-injection. As shown in Figure 2C and D, the temperature of both MNs-PEG/IR780-DOX and MNs-PEG/IR780-DOX + MF treated mice increased over 52°C within 2 min and then was maintained at 53°C. As a control, the temperature of PBS-treated mice did not increase over 40°C after NIR irradiation for 10 min.

To evaluate DOX release from MNs-PEG/IR780-DOX at different pH solutions, the MNs-PEG/IR780-DOX were placed for 12 h in solutions of pH 4.5, 6.0, or 7.4. The samples were tested for DOX release at selected time intervals using a UV-vis spectroscopy at 495 nm. We found that DOX release rates at pH 4.5 and 6.0 were approximately 3- and 2-times higher than at pH 7.4 (Figure 2E).

Additionally, we evaluated DOX release with or without NIR laser irradiation. As shown in Figure 2F, the cumulative released DOX was extremely low over 10 min without irradiation. However, when the MNs-PEG/IR780-DOX were irradiated by NIR laser, the release of DOX was about 1.2-fold higher than that in no NIR laser group, suggesting NIR




Figure 1 Schematic illustration of the synthesis and application of MNs-PEG/IR780-DOX. **(A)** The tumor growth and metastasis of orthotopic xenograft 4T1-luc-bearing mice. **(B)** MNs-PEG/IR780-DOX exhibited antitumor effects and prevented distant organs metastasis under NIR laser irradiation and MF, and alleviated tumor immunosuppressive microenvironment and duct administration.

laser-triggered drug release as a result of a photothermal effect on DOX from the MNs-PEG/IR780-DOX. Collectively, the DOX release from MNs-PEG/IR780-DOX could be triggered and promoted by decreasing solution pH and NIR laser and realizing a spatio-temporal control release.

Antitumor Efficacy of MNs-PEG/IR780-DOX in vitro

In general, anti-cancer drug relies on transport proteins on cell membranes, but nanomaterials always enter cells through endocytosis pathways,²⁶ which increases the uptake of drugs by cells. To determine whether MNs-PEG/IR780-DOX might result in enhanced DOX uptake by cells, the 4T1-luc cells were treated with free DOX or MNs-PEG/IR780-DOX for 1, 2, and 3 h (the concentration of DOX = 4 $\mu\text{g/mL}$). The cellular uptake of DOX was measured quantitatively by the fluorescence intensity per cell using flow cytometry. As shown in Figure 3A and B, DOX uptake increased with the incubation time in the free DOX group and the MNs-PEG/IR780-DOX group. However, at a particular time point, DOX uptake was higher in MNs-PEG/IR780-DOX group than in the free DOX group. In group MNs-PEG/IR780-DOX, the cell absorption rate reached 77% after incubation for 1 hour, while in free DOX, it was only 15.8%. With the extension of




Figure 2 Photothermal performance and drug release behavior of drug-loaded MNs-PEG/IR780-DOX. **(A)** Photothermal conversion capability of MNs-PEG/IR780-DOX. Temperature change response to 808 nm NIR laser (1.5 W/cm²) on and off in 1080 s. **(B)** Thermal images and elevation curves of deionized water (1.5 W/cm²) and MNs-PEG/IR780-DOX (0.5, 1.5 W/cm²) solution upon irradiation of 808 nm NIR laser for 5 min. **(C)** In vivo, infrared thermal images of the tumor sites in 4T1-luc-bearing mice irradiated immediately post i.duc injection with PBS, MNs-PEG/IR780-DOX, MNs-PEG/IR780-DOX + MF at 0 min, 0.5 min, 2 min, and 10 min after irradiation. **(D)** Temperature variation curves of the tumor sites in 4T1-luc-bearing mice after i.duc injection with different groups followed by NIR laser irradiation. **(E)** DOX release from MNs-PEG/IR780-DOX in PBS buffer at pH values of 7.4, 6.0, and 4.5. **(F)** DOX release from MNs-PEG/IR780-DOX with or without NIR laser irradiation. Data are shown as means \pm SD (n = 3). ***p < 0.001.

the incubation time, the cell absorption rate of MNs-PEG/IR780-DOX reached 93.0% after 3 h incubation, which was 4 times that of free DOX (21.1%).

To understand the localization of MNs-PEG/IR780-DOX in 4T1-luc cells, confocal laser scanning microscopy (CLSM) assay was performed. As shown in Figure 3C and D, no obvious DOX fluorescence was detected within 4T1-luc cells treated




Figure 3 Cytotoxicity of MNs-PEG/IR780-DOX *In vitro*. **(A and B)** Flow cytometry based quantitative analysis of cellular uptake of DOX in 4T1-luc cells after treatment with free DOX and MNs-PEG/IR780-DOX for 1, 2, and 3 h at 4 µg/mL concentrations of DOX. **(C and D)** Confocal microscopic image and mean fluorescence intensity of 4T1-luc cells incubated with free DOX and MNs-PEG/IR780-DOX for 3h, scale bars: 25 µm. **(E)** Cytotoxicity comparison of 4T1-luc cells incubated with free DOX or MNs-PEG/IR780-DOX for 48 h at different DOX concentrations. **(F)** *In vitro* cytotoxicity of PBS, MNs-PEG/IR780, Laser, MNs-PEG/IR780 + Laser, MNs-PEG/IR780-DOX + Laser (at equal DOX concentration with 4 µg/mL). Data are shown as means ± SD. #*p* > 0.05, **p* < 0.05, *****p* < 0.0001.

with the free DOX (MFI = 6.26), while solid DOX fluorescence appeared in the lysosomes and nuclei within cells treated with MNs-PEG/IR780-DOX (MFI = 33.66), which was approximately 5-fold higher than the free DOX group (MFI = 6.26).

Next, we performed the cell death assay of MNs-PEG/IR780-DOX against 4T1-luc cells by CCK-8 assay. Figure 3E shows that both free DOX and MNs-PEG/IR780-DOX showed cytotoxicity to the 4T1-luc cells in a dose-dependent

manner. However, MNs-PEG/IR780-DOX exhibited more pronounced tumor cell death effects; the IC₅₀ value was significantly lower for MNs-PEG/IR780-DOX (0.35 $\mu\text{g}/\text{mL}$) than Dox (7.85 $\mu\text{g}/\text{mL}$). In Figure 3F, none of the other groups could kill tumor cells; only the MNs-PEG/IR780-DOX+Laser group had a more vital killing ability and a stronger lethality than MNs-PEG/IR780-DOX, indicating that laser can enhance the ability to kill tumor cells. Together, these results indicated that MNs-PEG/IR780-DOX exhibited more vital anti-tumor ability by exhibiting more effectively endocytosed in 4T1-luc cells.

Dual System in vivo Imaging Examine Targeting and Retention in Tumor and Tissue of MNs-PEG/IR780-DOX

The safety and effectiveness of anticancer drugs via i.duc administration have been verified in the previous work.²⁷ However, the visual evidence of drug aggregation in the tumor is still lacking after intratumoral injection. Hence, we determined the permeability and retention of MNs-PEG/IR780-DOX in tumors by dual imaging of bioluminescence and NIR fluorescence.^{28,29} The tumor model consisted of i.duc injection of 20 μL of 4T1-luc cells (1×10^5 cells in PBS) into the 4th right mammary gland of each BALB/c mice under anesthesia. To evaluate the intratumoral retention of MNs-PEG/IR780-DOX, 20 μL of MNs-PEG/IR780-DOX (DOX, 1mg/kg) or PBS was administered i.duc into the 4th mammary gland of mice with or without MF. The bioluminescence images and NIR fluorescence were collected at different time points using the IVIS imaging system (Figure 4A). Fluorescence images of sections were also collected using a fluorescence microscope. As shown in Figure 4B, the fluorescence intensity of both groups was most potent at 3 h, and decreased with time. However, the fluorescence decreasing rate of the MNs-PEG/IR780-DOX + MF group was slower than that of the MNs-PEG/IR780-DOX group, indicating that MF further prolonged fluorescence retention in tumors. After 24 h post i.duc administration, frozen tumor sections were obtained and stained by DAPI-, and spontaneous fluorescence was measured at 570 nm, labeled the nucleus and DOX, respectively (Figure 4C and D). The 4T1-luc bioluminescence image overlaps well with NIR fluorescence images in vivo, suggesting that MNs-PEG/IR780-DOX penetrates well into the tumor.

Next, we used dual imaging to verify drug distribution in tumors and major organs in vivo and in vitro. The 4T1-luc tumor model described above was established. In vivo imaging system (IVIS) optical imaging was carried out at 24 h after i.duc administration to observe the accumulation of MNs-PEG/IR780-DOX in the tumors. A significantly enhanced MNs-PEG/IR780-DOX fluorescence signal was detected in the tumors in vivo and in vitro of 4T1-luc tumor-bearing mice (Figure 5A). The quantitative analysis (Figure 5B) of the fluorescent intensity in MNs-PEG/




Figure 4 Targeting and retention of MNs-PEG/IR780-DOX to the tumor. (A) Bioluminescence and NIR fluorescence imaging of 4T1-luc tumor-bearing BALB/c mice at 0, 1, 3, 6, 12 and 24 h after i.duc administration of MNs-PEG/IR780-DOX. (B) Total fluorescence intensity of MNs-PEG/IR780-DOX with or without MF. (C) Bioluminescence and NIR fluorescence images tumors from tumor-bearing mice at 24 h post-injection. (D) H&E staining and fluorescence images of primary tumors from tumor-bearing mice. The blue fluorescence signal indicates cell nuclei stained with DAPI; the red fluorescence signal indicates DOX. Scale bars: 50 μm .




Figure 5 Tumor and tissue distribution of MNs-PEG/IR780-DOX in vivo. **(A and B)** Bioluminescence and NIR fluorescence images and fluorescence intensity of tumor, heart, lung, liver, spleen, kidney and lymph nodes extracted from tumor-bearing mice. **(C)** The tissue slices stained with DAPI (blue) showed DOX (red) distribution in different major organs. **(D)** Quantification of the mean fluorescent intensity of DOX in tumors and major organs. RILN: right inguinal lymph nodes, LILN: left inguinal lymph nodes, RPLN: right popliteal lymph node, LPLN: left popliteal lymph node. Scale bars: 50 μm.

IR780-DOX accumulated in tumors at 24 h was significantly higher than that in other organs ($p < 0.05$). Fluorescence imaging and quantitative analysis in vitro of dissected tumor at 24 h showed similar results. Low-level accumulation was observed in major organs, including the liver, spleen, and kidney. Importantly, DOX accumulation in the heart of the MNs-PEG/IR780-DOX-treated mice was much lower than that in other organs. The staining of DAPI (blue) and DOX (red) in tissue slices (Figure 5C) and quantitative fluorescence signal analysis (Figure 5D) demonstrated the lowest amounts of DOX in the heart, followed by the kidney, liver, lungs, spleen, and LNs. Interestingly, the concentration of the drug in the lymph nodes and spleen was high, second only to the tumor, which might play a role in inhibiting distant metastasis of the tumor.

Antitumor Efficacy of MNs-PEG/IR780-DOX in vivo

To investigate the antitumor efficacy of MNs-PEG/IR780-DOX in vivo, an antitumor study was performed using the i.d. inoculation of mouse 4T1 luciferase cells. Therapy was initiated 3 days after tumor inoculation (Figure 6A). The 4T1-luc tumor-bearing mice were divided into six groups randomly, and 20 μL of PBS, or free DOX, MNs-PEG/IR780-DOX, MNs-PEG/IR780-DOX + MF, MNs-PEG/IR780-DOX + L, MNs-PEG/IR780-DOX + MF + L (DOX, 1 mg/kg) was i.d. administered. Each mouse in the NIR laser group was irradiated with an 808 nm at 0.5W/cm² for 10 min 3 h post-injection.

Two methods determined tumor volume in the mice. Tumor volume was measured by bioluminescence intensity by IVIS imaging. Before imaging, 300 μL of D-luciferin potassium salt buffer solution with a 15 mg/mL concentration was intraperitoneally injected into each mouse and then incubated for 9 min to maximize the bioluminescence signal intensity (Figure 6B). The tumor volume was also calculated at 3-day intervals up to the end of the experiment using the following formula: width² × length × 0.5. As shown in Figure 6C, tumor growth in mice treated with free DOX was slower than in the PBS group, but no statistical difference was observed on day 24. However, MNs-PEG/IR780-DOX, MNs-PEG/IR780-DOX + MF and MNs-PEG/IR780-DOX + L significantly inhibited tumor growth compared to PBS. More importantly, MNs-PEG/IR780-DOX combined with MF and NIR laser irradiation inhibited tumor growth more effectively than other treatment groups.

At the end of the treatment procedure, the tumor-bearing mice were sacrificed, and the resected tumors and spleens were photographed (Figure 6D and E) and weighed (Figures 6F and G). The average tumor weight of the MNs-PEG/IR780-DOX+MF+L group was significantly reduced (95.9%) in comparison to the control group. Together, these results indicate that the novel strategy is the most effective treatment for suppressing tumor growth.




Figure 6 Antitumor efficacy of MNs-PEG/IR780-DOX in vivo. (A) Schematic illustration of tumor model establishment and therapeutic diagram. Mice were inoculated with 4T1-luc cells and treated once on day 3. (B) Bioluminescence imaging of 4T1-luc tumor-bearing mice on day 3, 6, 9 and 12 ($n = 4$). (C) Tumor growth curves of mice bearing 4T1-luc tumor and receiving various therapeutic methods. (D) Representative in vivo images of tumor-bearing mice on day 24 in different groups. (E) Photograph of dissected tumors and spleens. (F and G) Comparison of tumor and spleen weight in mice in different treated groups. Data are shown as means \pm SD. $\#p > 0.05$; $*p < 0.05$, $**p < 0.01$, $***p < 0.001$, and $****p < 0.0001$ vs PBS group; $\&p < 0.05$, $\&\&p < 0.01$, $\&\&\&p < 0.0001$.

Anti-Metastatic Effects of MNs-PEG/IR780-DOX

We evaluate the inhibitory effect of MNs-PEG/IR780-DOX on the development of distant metastasis of tumor. At the predetermined time point (day 24), the mice were anesthetized and major organs (ie, lung, liver, kidney, and bone) were excised and scanned by IVIS imaging system, then were fixed with 4% paraformaldehyde and embedded in paraffin. The tissues and tumors were stained with hematoxylin and eosin (H&E) for further observation by optical microscopy.

As shown in Figure 7A and B, lung, liver, kidney, and bone metastases were observed in the PBS group, while lung and liver metastases were seen in free DOX, MNs-PEG/IR780-DOX, MNs-PEG/IR780-DOX + MF. Significantly, MNs-PEG/




Figure 7 Anti-metastatic effect of MNs-PEG/IR780-DOX. **(A)** Biofluorescence images of heart, liver, spleen, lung, kidney and bone collected from 4T1-luc tumor-bearing BALB/c mice on day 24. **(B)** Histopathology and photomicrographs of lung, liver, kidney, and bone were obtained from mice in different groups. The yellow arrow and dashed line indicate metastasis. Scale bars = 100 μ m.

IR780-DOX + MF + L group showed no distant organ metastasis. Consistent with the therapeutic effect, MNs-PEG/IR780-DOX combined with magnetic field and NIR laser irradiation effectively prevented distant organ metastasis.

MNs-PEG/IR780-DOX Alleviated the Tumor Immunosuppressive Microenvironment and Boosted Antitumor Immunity

In order to evaluate whether MNs-PEG/IR780-DOX can cause immunogenic death of tumor cells under L and MF, and change the tumor immunosuppressive microenvironment. Based on the tumor-forming model and the corresponding treatment above, tumor and spleen were obtained. One part was used to prepare single-cell suspension for flow cytology analysis, and the other part was analyzed by confocal imaging. As shown in Figure 8A–C, confocal laser analysis results showed that the infiltrating proportion of MDSCs ($CD11b^+GR1^+$) and Tregs ($CD4^+CD25^+$) was higher, but the cytotoxic T cells ($CD3^+CD8^+$) was lower in the PBS group than that of other groups. The proportion of MDSCs and Tregs were the




Figure 8 MNs-PEG/IR780-DOX alleviated the tumor immunosuppressive environment and boosted antitumor immunity. (A–C) Representative immunofluorescence images of MDSCs (CD11b⁺GR1⁺), Tregs (CD4⁺CD25⁺) and cytotoxic T cells (CD3⁺CD8⁺) in tumor sections from different groups (scale bar: 25 μ m). (D–F) Quantification of MDSCs, Tregs and cytotoxic T cells in tumors by flow cytometric analysis. (G) Quantification of cytotoxic T cells (CD3⁺CD8⁺) in spleens by flow cytometric analysis. n = 3, data are shown as means \pm SD. #p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

lowest and cytotoxic T cells were the highest in MNs-PEG/IR780-DOX + MF + L group. The flow cytometric analysis results are consistent with those of the flow analysis (Figure 8D–F). Additionally, MNs-PEG/IR780-DOX + MF + L could significantly increase the percentage of CD8⁺ T cells in spleens (Figure 8G). Examples of analyses of MDSCs and T cells subtypes are shown in Figures S5 and S6. According to the above data, MNs-PEG/IR780-DOX inhibited tumor growth and distant metastasis by alleviating the tumor immunosuppressive microenvironment and boosting antitumor immunity.

Safety and Tolerability of MNs-PEG/IR780-DOX via i.duc Administration

To evaluate the safety and tolerability of MNs-PEG/IR780-DOX, mice were divided into six groups randomly and administrated with 20 μ L of PBS, MNs-PEG/IR780-DOX, MNs-PEG/IR780-DOX + MF, MNs-PEG/IR780-DOX + L, MNs-PEG/IR780-DOX + MF + L (DOX, 1 mg/kg) by the i.duc route. The 4T1-luc tumor-bearing mice were sacrificed on day 21. Blood of the mice was collected for alanine aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), urea, creatinine (Cr), red blood cells (RBC), hemoglobin (HGB), white blood cells (WBC), and platelet (PLT) examination. The body weight of the mice was also recorded.

The H&E images confirmed no obvious damage or inflammatory infiltration in the major organs, including the liver, lung, kidney, and heart (Figure 9A), and treatments in mice did not influence the normal range of ALT, AST, ALP, urea, Cr, RBC,




Figure 9 Safety and tolerability of MNs-PEG/IR780-DOX via i.duc administration. **(A)** Histological H&E staining images of liver, lung, brain, spleen, kidney, and heart of healthy BALB/c mice 21 days after i.duc administration of different treatments ($n = 5$). **(B-J)** The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), creatinine (Cr), urea, red blood cells (RBC), hemoglobin (HGB), white blood cells (WBC), platelet (PLT) in different groups. **(K)** Body weight of mice subjected to different treatments. Data are shown as mean \pm SD. $^{*}p < 0.05$. Scale bars: 50 μ m.

HGB, WBC and PLT (Figure 9B-J). Additionally, no difference in body weight showed negligible difference among all groups, as shown in Figure 9K. Taken together, these results suggested that MNs-PEG/IR780-DOX combined with magnetic field and NIR laser irradiation was safe via i.duc administration.

Discussion

The long-standing paucity of effective therapies other than chemotherapy leads to TNBC being the subtype with the least favorable outcome.³⁰ Due to the lack of traditional targeted molecules (ER, PR, and HER2), TNBC is almost ineffective against endocrine and HER2 inhibitor therapy. Despite recent advances in omics technology, a better understanding of the tumor-immune system has promoted clinical trials of novel targeted drugs, including PARP inhibitors,³¹ antibody-drug conjugates antibody drug conjugates,³² and immune checkpoint inhibitors,^{33,34} providing new opportunities for TNBC patients. Trodelvy (Sacituzumab Govitecan) is the first targeted anticancer drug approved by the Food and Drug Administration (FDA) to treat patients with locally unresectable advanced or metastatic TNBC. However, it is only used as the third or later line of treatment.³⁵ Chemotherapy is still the primary systemic adjuvant therapy for TNBC patients.

DOX is one of the most commonly used chemotherapy agents in the treatment of TNBC. However, it has severe cardiotoxicity as a free drug.³⁶ DOX encapsulated by the nano-drug delivery system can increase tumor targeting and reduce toxicity.³⁷ Cancer combination therapy enhanced super-additive therapeutic outcomes, as mentioned above. This study achieved tumor-targeted aggregation and spatio-temporal precise release control through i.duc injection of MNs-PEG/IR780-DOX, thus improving antitumor efficacy and reducing drug toxicity.

The nano-photothermal preparation has high light absorption and photothermal conversion efficiency under the NIR window.³⁸ As previously described,^{39,40} IR780, a near-infrared fluorescence dye that allows for non-invasive imaging in live animals, is also an excellent photosensitizer for PTT. Photothermal tumor ablation was performed by Fe₃O₄ under near-infrared laser irradiation.^{41,42} Hence, we encapsulated the IR780 and DOX into PEG-Fe₃O₄ nanoparticles. Our results indicated that the photothermal conversion efficiency of MNs-PEG/IR780-DOX could reach 50.1%, which is 2.3 times that of gold nanoparticles (21%)⁴³ and is similar to that of platinum nanosheets (27.6–52%)⁴⁴ and outcompete that of PbS/CdS quantum dots (47.6%).⁴⁵ Additionally, the data indicated that under NIR laser irradiation, the MNs-PEG/IR780-DOX showed excellent warming curves both *in vitro* and *in vivo*, compared with the control group.

Since most cancer tissues have relatively lower extracellular pH (pH = 5.7–7.8), inside endosomal (pH = 5.5–6.0) and lysosomal (pH = 4.5–5.0) compartments, compared to normal tissues and bloodstream (pH = 7.4), pH-dependent releasing behavior ensures the controlled release around tumor sites and reduces undesired drug loss in blood circulation.⁴⁶ The DOX release of our designed material increases gradually with the decrease in pH value, which is a pH-sensitive release. This pH-dependent releasing behavior of DOX molecules from nanocarriers has been noted in previous literature.^{47–49} We noted that the DOX release from nanocarriers could be triggered and promoted by decreasing the solution pH < 4.5. The lower pH can enhance the release of DOX from the composite. DOX can be stimulated to release from MNs-PEG/IR780-DOX under NIR laser irradiation. Our research results show that nanomaterials can achieve spatio-temporal controlled release under low pH and NIR laser irradiation.

Numerous studies have shown that intraductal intervention is effective in breast cancer prevention and treatment.^{24,27,50,51} However, the tumor's visual evidence of drug aggregation is still lacking after intraductal injection. In this study, we demonstrated for the first time by dual-system in vivo imaging that significant accumulation of DOX via i.d. administration was found in tumors with very limited in other organs, especially in the heart. Interestingly, we found that DOX fluorescence was second strongest in inguinal and axillary lymph nodes, which may contribute to resisting distant tumor metastasis.

The tumor microenvironment (TME) comprises the surrounding blood vessels, immune cells, fibroblasts, signaling molecules and the extracellular matrix (ECM).⁵² The TME is an immunosuppressive microenvironment in which the number of cytotoxic T cells decreased,⁵³ and MDSCs and Tregs with immunosuppressive function increased.⁵⁴ Previous studies indicate that DOX⁵⁵ and PTT^{56,57} induced tumor cell immunogenic death (ICD), which results in an effective antitumor immune response through activation of dendritic cells (DCs) and consequent activation of specific T cell response, subsequently creating a highly immunogenic TME. Our study showed that intraductal injection of the MNs-PEG/IR780-DOX under NIR laser irradiation reduced the proportion of immunosuppressive cells while increasing cytotoxic T cell infiltration, sequentially reversed immunosuppressive TME. In addition, we also found that the proportion of CD8 cells in the spleen was activated in the MNs-PEG/IR780-DOX + MF+L group. Turning the immune-suppressive TME into a favorable milieu for activating antitumor T cell responses can induce potent antitumor immunity. Effective suppression of distant metastasis improves prognosis, as distant metastasis is the major cause of cancer-related death.⁵⁸

Although DOX is an effective chemotherapeutic agent, the cardiotoxicity associated with systemic administration significantly limits the clinical use of DOX.⁵⁹ However, this can be addressed by topical administration. It has been shown that intraductal therapy is safe in BC models. Stearns et al⁶⁰ i.d. administered five commonly used chemotherapeutic drugs, such as capecitabine, paclitaxel, PLD, 5-fluorouracil (5-FU), and methotrexate, and found that all of them could significantly inhibit the generation of breast cancer without significant toxicity. We detected the blood routine, liver and kidney function, and pathological examination of essential organs of mice treated with different treatments and found no significant differences with the control group. Also, there was no statistical difference in body weight, no apparent abnormal behavior, skin ulcers, depilation, and breast swelling.

Conclusion

Through i.d. administration, combined with the loading of photosensitivity (IR780) and DOX-magnetic nano-delivery systems, under the action of external MF and NIR laser, we achieved the precise and spatiotemporal controlled release of drugs (MNs-PEG/IR780-DOX), which effectively inhibited 4T1-luc transplanted tumors and metastasis of distant organs. The mechanism was to cause the immunogenic death of tumor cells and change the tumor immunosuppressive microenvironment

by increasing tumor infiltration of killer T cells and reducing the proportion of MDSCs cells. These findings provide a promising dual-targeted, minimally invasive, effective, and safe treatment for TNBC.

Abbreviations

TNBC, triple negative breast cancer; PTT, photothermal therapy; NIR, near-infrared; DOX, doxorubicin; i.duc, intraductal; MF, magnetic field; L, laser; HER2, human epidermal growth factor receptor 2; EPR, enhanced permeability and retention; HA, hyaluronic acid; DMEM, Dulbecco's modified Eagle's medium; TEM, transmission electron microscope; CLSM, confocal laser scanning microscopy; CCK8, Cell Counting Kit 8; LNs, lymph nodes; DLS, dynamic light scattering; MFI, mean fluorescence intensity; IVIS, in vivo imaging system; H&E, hematoxylin and eosin; ALT, alanine aminotransferase; AST, aspartate transaminase; ALP, alkaline phosphatase; Cr, creatinine; RBC, red blood cells; HGB, hemoglobin; WBC, white blood cells; PLT, platelet.

Consent for Publication

All the authors consent for publication.

Acknowledgments

J. Liu and L. Guo shared co-first authorship. J. Liu acknowledges the financial support from the National Natural Science Foundation of China (Grant No. 81802895) and the Health and Family Planning Commission of Wuhan Municipality (Grant No. WX17Q16). C. Chen acknowledges the Fundamental Research Funds for the Central Universities (Grant No. 2042019kf0229). S. Sun acknowledges the National Natural Science Foundation of China (NSFC) grant (Grant No: 81471781).

Disclosure

The authors report no conflicts of interest in this work.

References

- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209–249. doi:10.3322/caac.21660
- Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. *N Engl J Med.* 2010;363(20):1938–1948. doi:10.1056/NEJMra1001389
- Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience. *Nat Rev Clin Oncol.* 2010;7(12):683–692. doi:10.1038/nrclinonc.2010.154
- Metzger-Filho O, Tutt A, de Azambuja E, et al. Dissecting the heterogeneity of triple-negative breast cancer. *J Clin Oncol.* 2012;30(15):1879–1887. doi:10.1200/JCO.2011.38.2010
- Curigliano G, Cardinale D, Deri S, et al. Care toxicity of anticancer treatments: epidemiology, detection, and management. *CA Cancer J Clin.* 2016;66(4):309–325. doi:10.3322/caac.21341
- Zhang S, Liu X, Bawa-Halfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nat Med.* 2012;18(11):1639–1642. doi:10.1038/nm.2609
- Chen J, Zhu Y, Wu C, Shi X. Nanoparticle-based cascade engineering for cancer therapy. *Chem Soc Rev.* 2020;49(24):9057–9094. doi:10.1039/d0cs00607f
- Davis ME, Chen ZG, Lim DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. *Nat Rev Drug Discov.* 2008;7(9):771–782. doi:10.1038/nrd2614
- Mittapalli S, Liu X, Shen SE, et al. Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model. *Cancer Ther.* 2013;12(11):2389–2399. doi:10.1158/1535-7163.MCT-13-0132
- Morshed RA, Matuski ME, Dai Q, et al. Cell-penetrating peptide-modified gold nanoparticles for the delivery of doxorubicin to brain metastatic breast cancer. *Mol Pharm.* 2016;13(6):1843–1854. doi:10.1021/acs.molpharmaceut.6b00004
- Hamilton AM, Aidoudi-Ahmed S, Sharma S, et al. Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain. *J Mol Med.* 2015;93(9):991–1001. doi:10.1007/s00109-015-1279-x
- Li J, Cai P, Shalviri A, et al. A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer. *ACS Nano.* 2014;8(10):9925–9940. doi:10.1021/nn501069c
- Han L, Kong DK, Zheng MQ, et al. Increased nanoparticle delivery to brain tumors by autocatalytic priming for improved treatment and imaging. *ACS Nano.* 2016;10(4):4209–4218. doi:10.1021/acsnano.5b07573
- Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. *J Control Release.* 2011;153(3):198–205. doi:10.1016/j.jconrel.2011.06.001
- Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. *Nat Rev Clin Oncol.* 2010;7(11):653–664. doi:10.1038/nrclinonc.2010.139
- Doroshov JH, Simon RM. On the design of combination cancer therapy. *Cell.* 2017;171(7):1476–1478. doi:10.1016/j.cell.2017.11.035
- Faraji F, Hashemi M, Ghiasabadi A, et al. Combination therapy with interferon beta-1a and sesame oil in multiple sclerosis. *Complement Ther Med.* 2019;45:275–279. doi:10.1016/j.ctim.2019.04.010

18. Adeli F, Abbasi F, Babazadeh M, Davaran S. Thermo/pH dual-responsive micelles based on the host-guest interaction between benzimidazole-terminated graft copolymer and β -cyclodextrin-functionalized star block copolymer for smart drug delivery. *J Nanobiotechnology*. 2022;20(1):91. doi:10.1186/s12951-022-01290-3
19. Liu Y, Bhattarai P, Dai Z, Chen X. Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer. *Chem Soc Rev*. 2019;48(7):2053–2108. doi:10.1039/c8cs00618k
20. Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. *Proc Natl Acad Sci USA*. 2003;100(23):13549–13554. doi:10.1073/pnas.2232479100
21. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. *Nat Rev Immunol*. 2017;17(2):97–111. doi:10.1038/nri.2016.107
22. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. *Nat Med*. 2007;13(1):54–61. doi:10.1038/nm1523
23. Budker VG, Monahan SD, Subbotin VM. Loco-regional cancer drug therapy: present approaches and rapidly reversible hydrophobization (RRH) of the therapeutic agents as the future direction. *Drug Discov Today*. 2014;19(12):1855–1870. doi:10.1016/j.drudis.2014.08.009
24. Kuang XW, Liu JH, Sun ZH, Sukumar S, Sun SR, Chen C. Intraductal therapy in breast cancer: current status and future prospective. *J Mammary Gland Biol Neoplasia*. 2020;25(2):133–143. doi:10.1007/s10911-020-09453-4
25. Liu JH, Chen C, Li ZY, et al. The MyD88 inhibitor TJ-M2010-2 suppresses proliferation, migration and invasion of breast cancer cells by regulating MyD88/GSK-3 β and MyD88/NF- κ B signalling pathways. *Exp Cell Res*. 2020;394(2):112157. doi:10.1016/j.yexcr.2020.112157
26. Yin Q, Shen J, Zhang Z, Yu H, Li Y. Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor. *Adv Drug Deliv Rev*. 2013;65(13–14):1699–1715. doi:10.1016/j.addr.2013.04.011
27. Wang G, Chen C, Pai P, et al. Intraductal fulvestrant for therapy of ER α -positive ductal carcinoma in situ of the breast: a preclinical study. *Carcinogenesis*. 2019;40(7):903–913. doi:10.1093/carcin/bgz084
28. Huang L, Li Y, Du Y, et al. Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy. *Nat Commun*. 2019;10(1):4871. doi:10.1038/s41467-019-12771-9
29. Li J, Yu X, Jiang Y, et al. Second near-infrared photothermal semiconducting polymer nanoadjuvant for enhanced cancer immunotherapy. *Adv Mater*. 2021;33(4):e2003458. doi:10.1002/adma.202003458
30. Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. *Nat Rev Clin Oncol*. 2022;19(2):91–113. doi:10.1038/s41571-021-00565-2
31. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. *N Engl J Med*. 2018;379(8):753–763. doi:10.1056/NEJMoa1802905
32. Drago JZ, Modi S, Chandralapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. *Nat Rev Clin Oncol*. 2021;18(6):327–344. doi:10.1038/s41571-021-00470-8
33. Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. *N Engl J Med*. 2022;386(6):556–567. doi:10.1056/NEJMoa2112651
34. Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, Phase 3 trial. *Lancet*. 2020;396(10257):1090–1100. doi:10.1016/S0140-6736(20)31953-X
35. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab Govitecan-hz in refractory metastatic triple-negative breast cancer. *N Engl J Med*. 2019;380(8):741–751. doi:10.1056/NEJMoa1814213
36. Yang J, Bahreman A, Daudey G, Bussmann J, Olschewski S, Kros A. Drug delivery via cell membrane fusion using lipopeptide modified liposomes. *ACS Cent Sci*. 2016;2(9):627–630. doi:10.1021/acscentsci.6b00172
37. Wei Y, Song S, Duan N, et al. MT1-MMP-activated liposomes to improve tumor blood perfusion and drug delivery for enhanced pancreatic cancer therapy. *Adv Sci*. 2020;7(17):190174. doi:10.1002/advs.201902746
38. Pan S, Yin J, Yu L, et al. 3D MXene-integrated 3D-printing scaffolds for augmented osteosarcoma phototherapy and accelerated tissue reconstruction. *Adv Sci*. 2020;7(2):190151. doi:10.1002/advs.201901511
39. Zhang S, Deng G, Liu Y, et al. Autocatalytic delivery of brain tumor-targeting, size-shrinkable nanoparticles for treatment of breast cancer brain metastases. *Adv Funct Mater*. 2020;30(14). doi:10.1002/adfm.201910651
40. Kang J, Kim D, Song J, et al. Enhanced performance of a molecular photoacoustic imaging agent by encapsulation in mesoporous silicon nanoparticles. *Adv Mater*. 2018;30(27):1800512. doi:10.1002/adma.201800512
41. Chen C, Huang G, Zhu S, et al. In situ electric-induced switchable transparency and wettability on laser-ablated bioinspired paraffin-impregnated slippery surfaces. *Adv Sci*. 2021;8(14):e2100701. doi:10.1002/advs.202100701
42. Fan Y, Yuan Y, Shou C, et al. cRGD-conjugated Fe(3)O(4)@PDA-DOX multifunctional nanocomposites for MRI and antitumor chemophotothermal therapy. *Int J Nanomedicine*. 2019;14:9631–9645. doi:10.2147/IJN.S222797
43. Cheng L, Wang C, Feng L, Yang K, Liu Z. Functional nanomaterials for phototherapies of cancer. *Chem Rev*. 2014;114(21):10869–10939. doi:10.1021/cr400532z
44. Tang S, Chen M, Zheng N. Sub-10-nm Pd nanosheets with renal clearance for efficient near-infrared photothermal cancer therapy. *Small*. 2014;10(15):3139–3144. doi:10.1002/smll.201303631
45. Huang LY, Zhu S, Cui R, Zhang M. Noninvasive in vivo imaging in the second near-infrared window by inorganic nanoparticle-based fluorescent probes. *Anal Chem*. 2020;92(1):535–542. doi:10.1021/acs.analchem.9b04156
46. Xing L, Zheng H, Cao Y, Che S. Coordination polymer coated mesoporous silica nanoparticles for pH-responsive drug release. *Adv Mater*. 2012;24(48):6433–6437. doi:10.1002/adma.201201742
47. Fang W, Tang S, Liu P, Fang X, Gong J, Zheng N. Pd nanosheet-covered hollow mesoporous silica nanoparticles as a platform for the chemo-photothermal treatment of cancer cells. *Small*. 2012;8(24):3816–3822. doi:10.1002/smll.201200962
48. Shalviri A, Raval G, Prasad P, et al. pH-Dependent doxorubicin release from terpolymer of starch, polymethacrylic acid and polysorbate 80 nanoparticles for overcoming multi-drug resistance in human breast cancer cells. *Eur J Pharm Biopharm*. 2012;82(3):587–597. doi:10.1016/j.ejpb.2012.09.001

49. Wang Y, Zhao R, Wang S, Liu Z, Tang R. In vivo dual-targeted chemotherapy of drug resistant cancer by rationally designed nanocarrier. *Biomaterials*. 2016;75:71–81. doi:10.1016/j.biomaterials.2015.09.030
50. Chun YS, Bisht S, Chenna V, et al. Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCure) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: implications for breast cancer chemoprevention in at-risk populations. *Carcinogenesis*. 2012;33(11):2242–2249. doi:10.1093/carcin/bgs248
51. Murata S, Kominsky SL, Vali M, et al. Ductal access for prevention and therapy of mammary tumors. *Cancer Res*. 2006;66(2):638–645. doi:10.1158/0008-5472.CAN-05-4329
52. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. *Science*. 2015;348(6230):74–80. doi:10.1126/science.aaa6204
53. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science*. 2011;331(6024):1565–1570. doi:10.1126/science.1203486
54. Shurin MR. Osteopontin controls immunosuppression in the tumor microenvironment. *J Clin Invest*. 2018;128(12):5209–5212. doi:10.1172/JCI124918
55. Garg AD, Galluzzi L, Apetoh L, et al. Molecular and translational classifications of DAMPs in immunogenic cell death. *Front Immunol*. 2015;6:588. doi:10.3389/fimmu.2015.00588
56. Brotons-Gisbert M, Branny A, Kumar S, et al. Coulomb blockade in an atomically thin quantum dot coupled to a tunable Fermi reservoir. *Nat Nanotechnol*. 2019;14(5):442–446. doi:10.1038/s41565-019-0402-5
57. Phuengkham H, Ren L, Shin IW, Lim YT. Nanoengineered immune niches for reprogramming the immunosuppressive tumor microenvironment and enhancing cancer immunotherapy. *Adv Mater*. 2019;31(34):e1803322. doi:10.1002/adma.201803322
58. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. *Nat Rev Cancer*. 2002;2(8):563–572. doi:10.1038/nrc865
59. Yang FW, Wang H, Wang C, Chi GN. Retraction. *J Cell Biochem*. 2021;122(Suppl 1):S134. doi:10.1002/jcb.32221
60. Stearns V, Mori T, Jacobs LK, et al. Preclinical and clinical evaluation of intraductally administered agent in early breast cancer. *Sci Transl Med*. 2011;3(106):106ra108. doi:10.1126/scitranslmed.3002368

RETRACTED

International Journal of Nanomedicine

Dovepress

Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-nanomedicine-journal>